![]() |
市場調査レポート
商品コード
1614780
TLC590市場:市場規模、予測、新たな洞察-2032年TLC590 Market Size, Forecast, and Emerging Insight - 2032 |
||||||
カスタマイズ可能
適宜更新あり
|
TLC590市場:市場規模、予測、新たな洞察-2032年 |
出版日: 2024年12月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
Taiwan Liposome Company(TLC)は、一般的な麻酔薬であるロピバカインに徐放性送達技術を導入した、速効性、持続性、非オピオイド性の術後局所麻酔薬TLC590を開発しており、術後疼痛に対する局所麻酔の投与回数を減らすことを意図しています。より効果的な鎮痛により、患者は術後疼痛治療にしばしば用いられるオピオイド療法の問題を回避することもできます。
ブピバカインとロピバカインは術後痛によく使用されますが、半減期が比較的短いという問題があります。ロピバカインはアミノアミド系の長時間作用型局所麻酔薬で、神経線維の電位依存性ナトリウムチャネルを可逆的に阻害することにより疼痛管理に広く用いられています。ブピバカインよりも心毒性と中枢神経系毒性が低く、TLC590の活性薬です。
当レポートでは、主要7ヶ国におけるTLC590市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"TLC590 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about TLC590 for Postoperative pain in the seven major markets. A detailed picture of the TLC590 for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TLC590 for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TLC590 market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.
Taiwan Liposome Company (TLC) is developing TLC590, a fast onset, long-lasting, nonopioid postsurgical local anesthetic that brings sustained release delivery technology to the common anesthetic ropivacaine, intending to reduce the frequency of administration for local anesthesia for postsurgical pain. More effective pain relief may also allow patients to avoid the problems of opioid therapies often used to treat postsurgical pain.
Bupivacaine and ropivacaine are frequently used for postsurgical pain; however, they suffer from a relatively short half-life. Ropivacaine, an amino-amide long-acting local anesthesia drug, is widely used in pain management by reversibly inhibiting the voltage-gated sodium channels in nerve fibers. It exhibits reduced cardiotoxicity and CNS toxicity than bupivacaine and is the active drug in TLC590.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TLC590 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of TLC590 for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of TLC590 for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.